Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Obesity Right
  3. Zepbound (tirzepatide) injection Right
  4. Can the Zepbound® (tirzepatide) dose be split into smaller doses when using the KwikPen®?
Search Zepbound (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Zepbound ® (tirzepatide) injection

2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Can the Zepbound® (tirzepatide) dose be split into smaller doses when using the KwikPen®?

The Zepbound KwikPen contains 4 fixed doses; one 0.6 mL dose is taken weekly. Per the instructions for use, the KwikPen in-use period is 30 days after first use. Therefore, it is not recommended to split into smaller doses.

US_cFAQ_TZP374_Z_KWIKPEN_DOSE_SPLITTING_T2D_CWM
US_cFAQ_TZP374_Z_KWIKPEN_DOSE_SPLITTING_T2D_CWMen-US

See important safety information, including boxed warning, in the attached prescribing information.

Can the Dose be Split With Zepbound KwikPen?

The Zepbound KwikPen is a disposable multidose single-patient-use prefilled pen. The KwikPen contains 4 fixed doses, one dose taken weekly. Inject 0.6 mL in a single weekly injection, under the skin (subcutaneously).1

The Zepbound KwikPen Instructions for Use do not provide instructions for dialing a dose less than the full fixed dose, and therefore this is not recommended. When injecting Zepbound using Kwikpen, do not count clicks as you select the dose.1

After 4 doses, throw away (discard) the KwikPen, including the unused medication.1

Do not transfer Zepbound from your KwikPen into a syringe.1

Throw away the Zepbound KwikPen 30 days after first use even though the KwikPen has medication left in it.1

Please follow the approved Instructions for Use for proper storage, handling, and administration of the Zepbound KwikPen.

Why Should the Zepbound KwikPen be Discarded 30 Days After First Use?

The in-use period testing ensures that during the period of time once the multi-dose container is opened or punctured by a needle, the medicine stays good and meets certain criteria of quality.2

Testing of the Zepbound KwikPen was sufficient to support an in-use period of 30 days.1

Eli Lilly and Company cannot provide treatment recommendations for the use of Zepbound KwikPen beyond the 30-days in-use period.

Enclosed Prescribing Information

ZEPBOUND® (tirzepatide) injection, for subcutaneous use, Lilly

References

The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).

1Zepbound KwikPen [instructions for use]. Indianapolis, IN: Eli Lilly and Company; 2026.

2Chavda H. In-use stability studies: guidelines and challenges. Drug Dev Ind Pharm. 2021;47(9):1373-1391. https://doi.org/10.1080/03639045.2021.1994991

Date of Last Review: January 20, 2026

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.53 05/2026 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2026. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly